- Company
- Genome & Co acquires US firm to enter CDMO business
- by An, Kyung-Jin Sep 9, 2021 05:55am
- The KOSDAQ listed Genome & Company has acquired a manufacturing facility in the US to enter the microbiome contract development and manufacturing organization (CDMO) business. Through the acquire, the company aims to rise to a leader in both R&D and production in the microbiome market, a field with high growth potential. On the 8th, Genom
- Company
- Leclaza can be prescribed at general hospitals
- by An, Kyung-Jin Sep 9, 2021 05:54am
- Leclaza(Lazertinib Mesylate Monohydrate), a new domestic drug, is targeting the domestic lung cancer treatment market. As more than 30 major medical institutions nationwide were able to prescribe in about eight months of domestic permission, it has entered the domestic market competition, which forms 150 billion won a year. According to t
- Company
- Alunbrig proves the effectiveness of epilepsy patients
- by Sep 9, 2021 05:54am
- Competition is fierce for the first standard treatment as the second and third generation drugs, which are next-generation drugs, appear one after another in the ALK-positive non-small cell lung cancer treatment market. Target anticancer drugs targeting ALK mutations include the first generation Xalkori (Crizotinib), the second generation Zy
- Company
- It would have been a big trouble if no improvement
- by Chon, Seung-Hyun Sep 8, 2021 06:07am
- Pharmaceutical companies are actively working on transferring drug copyrights. As drug prices of transfer and transfer drugs are allowed, the transfer of permission rights due to mergers and acquisitions or corporate separation is speeding up. It is trying to enter the new generic market by receiving expensive products from other companies. A
- Opinion
- Clear standards needed for direct purchase of drugs overseas
- by Kim JiEun Sep 8, 2021 06:06am
- The world’s leading online e-commerce platform Amazon joined forces with one of the top e-commerce companies in Korea to set foot into the Korean market. The entry of this global direct purchasing giant into Korea had raised industry concerns that it would increase the illegal direct purchase of pharmaceuticals overseas and void the gove
- Policy
- Proposal of a bill to abolish special cases for Jeju
- by Lee, Jeong-Hwan Sep 8, 2021 06:05am
- A bill has been proposed by the National Assembly to abolish special cases for the opening of Jeju for-profit hospitals. The move is aimed at resolving the controversy over the establishment of for-profit hospitals by deleting special cases for opening foreign medical institutions. On the 7th, Representative Wi Sung-gon of Democratic Party
- Policy
- 3 companies voluntarily recall varenicline products
- by Lee, Jeong-Hwan Sep 8, 2021 06:05am
- Results of the safety investigation conducted by the Ministry of Food and Drug Safety on the N-nitroso-varenicline (NNV) impurity that was found in the smoking-cessation aid varenicline showed that the impurity’s risk of harming the human body was very low. However, all drugs that contain over ‘733ng (nanograms)/day’ of NNV will be
- Policy
- GSK's Shingrix has been granted
- by Lee, Tak-Sun Sep 8, 2021 06:05am
- GSK's shingles virus vaccine has been approved in Korea. As a result, competition between MSD and SK Bioscience is expected to take place for the lead in the market. The MFDS approved GSK's gene recombinant shingles vaccine Shingrix on the 6th. This product is a vaccine used to prevent shingles in adults over the age of 50 and those who a
- Policy
- Roche’s Herceptin+Perjeta combo is approved in Korea
- by Lee, Tak-Sun Sep 7, 2021 05:53am
- Roche’s developed a fixed-dose combination using two of its breast cancer treatments, Herceptin (trastuzumab) and Perjeta (pertuzumab). The Ministry of Food and Drug Safety approved Roche Korea’s ‘Phesgo (trastuzumab/pertuzumab) on the 6th. Trastuzumab and pertuzumab are commonly used ingredients for breast cancer. The original bra
- Policy
- The request for Zolgensma's benefit is growing
- by Lee, Jeong-Hwan Sep 7, 2021 05:53am
- Although only one intravenous administration has proven to be nearly cured of spinal muscular dystrophy (SMA), the administration costs about &8361;2.5 billion, increasing the demand for insurance benefits for Zolgensma (Onasemnogene Abeparvovec), which is called an "extremely high-priced one-shot treatment. Following the U.S. and Japan,
